Boston Trust Walden Corp Sells 2,997 Shares of Pfizer Inc. (NYSE:PFE)

Boston Trust Walden Corp cut its holdings in Pfizer Inc. (NYSE:PFE) by 4.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 72,582 shares of the biopharmaceutical company’s stock after selling 2,997 shares during the period. Boston Trust Walden Corp’s holdings in Pfizer were worth $2,031,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $36,000. HTLF Bank bought a new stake in Pfizer in the 4th quarter valued at $895,000. Davidson Trust Co. lifted its stake in Pfizer by 5.9% in the 4th quarter. Davidson Trust Co. now owns 14,743 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 815 shares in the last quarter. Resonant Capital Advisors LLC boosted its holdings in shares of Pfizer by 11.1% during the 4th quarter. Resonant Capital Advisors LLC now owns 97,898 shares of the biopharmaceutical company’s stock valued at $2,818,000 after purchasing an additional 9,762 shares during the last quarter. Finally, RIA Advisory Group LLC purchased a new position in shares of Pfizer during the fourth quarter valued at about $371,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wells Fargo & Company boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Price Performance

Pfizer stock opened at $28.30 on Monday. The firm has a market capitalization of $160.36 billion, a PE ratio of -471.67, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.19. The firm has a 50-day moving average price of $28.75 and a 200-day moving average price of $27.91. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.67 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 2.68 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.94%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.